NeuroPace, Inc. (NPCE)
|Net Income (ttm)||-24.28M|
NeuroPace, Inc. has filed to go public with an IPO on the NASDAQ.
NeuroPace is a commercial-stage medical device company focused on transforming the lives of people suffering from epilepsy by reducing or eliminating the occurrence of debilitating seizures. Our novel and differentiated RNS System is the first and only commercially available, brain-responsive neuromodulation system that delivers personalized, real-time treatment at the seizure source. By continuously monitoring the brain’s electrical activity, recognizing patient-specific abnormal electrical patterns, and responding in real time with impercep... [Read more...]
|IPO Date |
Apr 21, 2021
|Stock Exchange |
|Ticker Symbol |
In 2020, NeuroPace's revenue was $41.14 million, an increase of 11.27% compared to the previous year's $36.97 million. Losses were -$24.28 million, -19.00% less than in 2019.